WO2021174594A1 - Anticorps monoclonal contre le nouveau coronavirus et son utilisation - Google Patents

Anticorps monoclonal contre le nouveau coronavirus et son utilisation Download PDF

Info

Publication number
WO2021174594A1
WO2021174594A1 PCT/CN2020/079718 CN2020079718W WO2021174594A1 WO 2021174594 A1 WO2021174594 A1 WO 2021174594A1 CN 2020079718 W CN2020079718 W CN 2020079718W WO 2021174594 A1 WO2021174594 A1 WO 2021174594A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
monoclonal antibody
seq
antigen
binding fragment
Prior art date
Application number
PCT/CN2020/079718
Other languages
English (en)
Chinese (zh)
Inventor
刘磊
刘映霞
沈晨光
吴燕
谭曙光
李德林
王非然
高福
Original Assignee
深圳市第三人民医院
中国科学院微生物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市第三人民医院, 中国科学院微生物研究所 filed Critical 深圳市第三人民医院
Publication of WO2021174594A1 publication Critical patent/WO2021174594A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to the field of immunology and molecular virology, especially the field of diagnosis, prevention and treatment of new coronaviruses.
  • the present invention relates to monoclonal antibodies against the novel coronavirus, and compositions containing the antibodies (for example, diagnostic agents and therapeutic agents).
  • the present invention also relates to the use of the antibody.
  • the antibody of the present invention can be used to diagnose, prevent and/or treat a novel coronavirus infection and/or diseases caused by the infection (for example, novel coronavirus pneumonia).
  • the new type of coronavirus 2019-nCoV is the pathogen that causes the new type of coronavirus pneumonia (COVID-19). It is a single-stranded RNA virus. It is the same as the severe acute respiratory syndrome coronavirus (SARS-CoV) and The Middle East respiratory syndrome coronavirus (MERS-CoV) that caused the outbreak in 2012 belongs to the coronavirus family.
  • the spike protein (Spike, S protein) on the surface of the virus binds to the host cell receptor angiotensin-converting enzyme 2 (ACE2) molecule in the process of infecting the host, thereby initiating the fusion of the viral membrane with the host cell membrane, causing the host cell to be infected with the virus .
  • the S protein is divided into two parts, S1 and S2. Studies have confirmed that the receptor binding domain (RBD) of the C-terminal (CTD) of S1 binds to ACE2 and mediates the process of membrane fusion.
  • antibody refers to an immunoglobulin molecule usually composed of two pairs of polypeptide chains (each pair has a "light” (L) chain and a “heavy” (H) chain).
  • Antibody light chains can be classified into kappa and lambda light chains.
  • Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA, and IgE, respectively.
  • the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 3 or more amino acids.
  • Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH).
  • the heavy chain constant region is composed of 3 domains (CH1, CH2, and CH3).
  • Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL).
  • the light chain constant region consists of a domain CL.
  • the constant region of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (for example, effector cells) and the first component (C1q) of the classical complement system.
  • the VH and VL regions can also be subdivided into regions with hyperdenaturation (called complementarity determining regions (CDR)), interspersed with more conservative regions called framework regions (FR).
  • CDR complementarity determining regions
  • Each VH and VL is composed of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxy terminus.
  • the variable regions (VH and VL) of each heavy chain/light chain pair respectively form the antibody binding site.
  • the allocation of amino acids to each region or domain follows Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917 ; Definition of Chothia et al. (1989) Nature 342:878-883.
  • antibody is not limited by any specific method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies.
  • the antibodies may be antibodies of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.
  • the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody It is also called “antigen binding part” for specific binding to antigen. See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd edition, Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Recombinant DNA technology can be used. Or through the enzymatic or chemical cleavage of intact antibodies to produce antigen-binding fragments of antibodies.
  • antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb, and complementarity determining regions (CDR) Fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, and such polypeptides, which comprise at least a portion of an antibody sufficient to confer specific antigen-binding ability to the polypeptide.
  • CDR complementarity determining regions
  • the antigen-binding fragment of the antibody is a single-chain antibody (e.g., scFv), in which the VL and VH domains pair to form a monovalent molecule by pairing a linker that enables it to be produced as a single polypeptide chain (see, e.g., Bird et al. , Science 242: 423 426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879 5883 (1988)).
  • scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH.
  • Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof.
  • a linker having an amino acid sequence (GGGGS) 4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448).
  • Other linkers that can be used in the present invention are described by Alfthan et al. (1995), Protein Eng. 8: 725-731, Choi et al. (2001), Eur. J. Immunol. 31: 94-106, Hu et al. (1996), Cancer Res. 56: 3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293: 41-56 and Roovers et al. (2001), Cancer Immunol.
  • the antigen-binding fragments of antibodies are diabodies, ie, diabodies, in which the VH and VL domains are expressed on a single polypeptide chain, but a linker that is too short is used to allow two structures in the same chain Pairing between the domains, thereby forcing the domain to pair with the complementary domain of the other chain and creating two antigen binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci. USA 90: 6444 6448 ( 1993), and Poljak RJ et al., Structure 2:1112 1123 (1994)).
  • antigen-binding fragments e.g., The above-mentioned antibody fragments
  • antigen-binding fragments of antibodies are specifically screened in the same manner as used for intact antibodies.
  • antibody includes not only intact antibodies but also antigen-binding fragments of antibodies.
  • the term "monoclonal antibody” refers to an antibody or a fragment of an antibody from a group of highly homologous antibody molecules, that is, a group of identical antibodies, except for natural mutations that may occur spontaneously. Antibody molecule.
  • the monoclonal antibody has high specificity for a single epitope on the antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen.
  • Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. (Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (for example, see Journal of virological methods, 2009, 158(1-2): 171-179).
  • neutralizing antibody refers to an antibody or antibody fragment that can eliminate or significantly reduce the virulence (for example, the ability to infect cells) of the target virus.
  • E. coli expression system refers to an expression system composed of E. coli (strain) and a vector, wherein E. coli (strain) is derived from a strain available on the market, such as but not limited to: GI698 , ER2566, BL21 (DE3), B834 (DE3), BLR (DE3).
  • the term "vector” refers to a nucleic acid delivery vehicle into which polynucleotides can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into the host cell through transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
  • Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or artificial chromosomes (PAC) derived from P1; bacteriophages such as lambda Bacteriophage or M13 phage and animal virus etc.
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillary viruses.
  • Polyoma vacuole virus (such as SV40).
  • a vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes.
  • the vector may also contain an origin of replication site.
  • the term "host cell” refers to a cell that can be used to introduce a vector, which includes, but is not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, and fungal cells such as yeast cells or Aspergillus , Such as insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.
  • prokaryotic cells such as Escherichia coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus
  • insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.
  • the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen to which it is directed.
  • an antibody that specifically binds to a certain antigen means that the antibody has a concentration of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, The affinity (KD) of 10 -8 M, 10 -9 M, or 10 -10 M or less binds to the antigen.
  • KD refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding, and the higher the affinity between the antibody and the antigen.
  • the antibody for example, the monoclonal antibody B38 of the present invention
  • the antibody is less than about 10 -5 M, such as less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, or 10 -10 M or
  • the smaller dissociation equilibrium constant (KD) binds to the antigen (for example, the RBD of the new coronavirus S protein), for example, as measured in a BIACORE instrument using surface plasmon resonance (SPR).
  • amino acids are usually represented by one-letter and three-letter abbreviations well known in the art.
  • alanine can be represented by A or Ala.
  • neutralizing activity refers to the ability of an antibody or antibody fragment to bind to the antigen protein on the virus, thereby preventing the virus from infecting cells and/or the maturation of the virus progeny and/or the release of the virus progeny Antibodies or antibody fragments with neutralizing activity can prevent the amplification of the virus, thereby inhibiting or eliminating the infection of the virus.
  • new coronavirus and “2019-nCoV” refer to a type of coronavirus that was discovered in cases of viral pneumonia at the end of 2019. The two have the same meaning and can be used interchangeably.
  • new coronavirus pneumonia and “COVID-19” refer to pneumonia caused by a new coronavirus infection. The two have the same meaning and can be used interchangeably.
  • the inventor of the present application discovered an antibody that can specifically recognize and target the S protein of the new coronavirus, especially the receptor binding domain (RBD) of the S protein, and can block the S protein.
  • RBD receptor binding domain
  • ACE2 cell receptor angiotensin-converting enzyme 2
  • the antibody of the present invention is particularly suitable for diagnosing, preventing and treating novel coronavirus infection or diseases related to novel coronavirus infection (for example, novel coronavirus pneumonia).
  • a monoclonal antibody or an antigen-binding fragment thereof which comprises the variable heavy region (VH) complementarity determining region of the amino acid sequence shown in SEQ ID NO: 1-3, respectively 1-3 (CDR1-3); and/or, the amino acid sequence of the light chain variable region (VL) complementarity determining region 1-3 (CDR1-3) shown in SEQ ID NO: 4-6, respectively.
  • VH variable heavy region
  • VL light chain variable region
  • the monoclonal antibody includes a heavy chain variable region (VH) as shown in SEQ ID NO:7.
  • VH heavy chain variable region
  • the monoclonal antibody includes a light chain variable region (VL) as shown in SEQ ID NO: 8.
  • VL light chain variable region
  • the monoclonal antibody comprises: the amino acid sequence is shown in SEQ ID NO: 1-3, VH CDR1-3, and the amino acid sequence is shown in SEQ ID NO: 4-6, respectively VL CDR1-3.
  • the monoclonal antibody includes: VH as shown in SEQ ID NO: 7 and VL as shown in SEQ ID NO: 8.
  • the monoclonal antibody also has a leader sequence at the N-terminus of the variable region of the heavy chain.
  • the leader sequence has an amino acid sequence as shown in SEQ ID NO: 11.
  • the monoclonal antibody also has a leader sequence at the N-terminus of the variable region of the light chain.
  • the leader sequence has an amino acid sequence as shown in SEQ ID NO: 11.
  • the monoclonal antibody or antigen-binding fragment thereof is selected from the group consisting of Fab, Fab', F(ab') 2 , Fd, Fv, dAb, complementarity determining region fragments, single-chain antibodies (e.g., scFv), human antibody, chimeric antibody or bispecific or multispecific antibody.
  • the monoclonal antibody further includes a heavy chain constant region.
  • the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO: 9.
  • the monoclonal antibody further includes a light chain constant region.
  • the amino acid sequence of the light chain constant region is shown in SEQ ID NO: 10.
  • the light chain of the monoclonal antibody is of ⁇ type.
  • the monoclonal antibody or antigen-binding fragment thereof can specifically bind to the spike protein (S protein) of the novel coronavirus. In certain preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof can target the receptor binding domain (RBD) of the spike protein (S protein) of the novel coronavirus. In certain preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof can inhibit the receptor binding and/or membrane fusion process mediated by the receptor binding domain (RBD) of the S protein, and inhibit virus infection of cells .
  • RBD receptor binding domain
  • the monoclonal antibody or antigen-binding fragment thereof has a neutralizing ability (for example, it can neutralize a novel coronavirus). In some preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof can inhibit the infection or entry of the new coronavirus into host cells. Thus, the monoclonal antibody or its antigen-binding fragment can neutralize the novel coronavirus, and thereby prevent and treat the infection of the novel coronavirus.
  • the application also provides an isolated nucleic acid molecule, which encodes the monoclonal antibody or antigen-binding fragment thereof of the present invention.
  • nucleic acid molecules are not limited to the method of their production, and can be obtained using genetic engineering recombination techniques or chemical synthesis methods.
  • the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence capable of encoding an antibody heavy chain variable region, wherein the antibody heavy chain variable region comprises: the amino acid sequence is SEQ ID NO: 1-3 of VHCDR1-3.
  • the antibody heavy chain variable region has an amino acid sequence as shown in SEQ ID NO:7.
  • the nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO: 12.
  • the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence capable of encoding an antibody light chain variable region, wherein the antibody light chain variable region comprises: the amino acid sequence is SEQ ID NO: 4- 6 VL CDR1-3.
  • the antibody light chain variable region has an amino acid sequence as shown in SEQ ID NO: 8.
  • the nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO: 13.
  • the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence capable of encoding a variable region of an antibody heavy chain as defined above, and a nucleotide sequence capable of encoding a variable region of an antibody light chain as defined above. Nucleotide sequence.
  • the antibody heavy chain variable region has an amino acid sequence as shown in SEQ ID NO:7.
  • the nucleotide sequence capable of encoding the variable region of the antibody heavy chain has the nucleotide sequence shown in SEQ ID NO: 12.
  • the nucleic acid molecule further comprises a nucleotide sequence encoding a leader sequence, which is located at the 5'end of the nucleotide sequence capable of encoding the variable region of the antibody heavy chain.
  • the leader sequence has an amino acid sequence as shown in SEQ ID NO: 11.
  • the nucleotide sequence encoding the leader sequence has the nucleotide sequence shown in SEQ ID NO: 16.
  • the antibody light chain variable region includes the amino acid sequence shown in SEQ ID NO: 8.
  • the nucleotide sequence capable of encoding the variable region of the antibody light chain has the nucleotide sequence shown in SEQ ID NO: 13.
  • the nucleic acid molecule further comprises a nucleotide sequence encoding a leader sequence, which is located at the 5'end of the nucleotide sequence capable of encoding the variable region of the antibody light chain.
  • the leader sequence has an amino acid sequence as shown in SEQ ID NO: 11.
  • the nucleotide sequence encoding the leader sequence has the nucleotide sequence shown in SEQ ID NO: 16.
  • the isolated nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 12 and the nucleotide sequence shown in SEQ ID NO: 13.
  • the isolated nucleic acid molecule comprises a first polynucleotide comprising a nucleotide sequence encoding a leader sequence and a nucleotide sequence capable of encoding the variable region of an antibody heavy chain; and,
  • the second polynucleotide includes a nucleotide sequence encoding a leader sequence and a nucleotide sequence capable of encoding the variable region of the antibody light chain.
  • the isolated nucleic acid molecule comprises a first polynucleotide, which comprises the nucleotide sequence shown in SEQ ID NO: 16 and the nucleoside shown in SEQ ID NO: 12 Acid sequence; and, the second polynucleotide, which comprises the nucleotide sequence shown in SEQ ID NO: 16 and the nucleotide sequence shown in SEQ ID NO: 13.
  • the isolated nucleic acid molecule further comprises a nucleotide sequence capable of encoding the constant region of the antibody heavy chain.
  • the heavy chain constant region has an amino acid sequence as shown in SEQ ID NO:9.
  • the nucleotide sequence capable of encoding the constant region of the antibody heavy chain has the nucleotide sequence shown in SEQ ID NO: 14.
  • the isolated nucleic acid molecule further comprises a nucleotide sequence capable of encoding the constant region of the antibody light chain.
  • the light chain constant region has an amino acid sequence as shown in SEQ ID NO: 10.
  • the nucleotide sequence capable of encoding the constant region of the antibody light chain has the nucleotide sequence shown in SEQ ID NO: 15.
  • the isolated nucleic acid molecule comprises a first polynucleotide, which comprises a nucleotide sequence encoding a leader sequence, a nucleotide sequence capable of encoding the variable region of an antibody heavy chain, and a nucleotide sequence capable of encoding The nucleotide sequence of the constant region of the antibody heavy chain; and, the second polynucleotide comprising a nucleotide sequence encoding a leader sequence, a nucleotide sequence capable of encoding the variable region of the antibody light chain, and a nucleotide sequence capable of encoding the antibody light chain The nucleotide sequence of the constant region.
  • the isolated nucleic acid molecule comprises a first polynucleotide, which comprises the nucleotide sequence shown in SEQ ID NO: 16, SEQ ID NO: 12 and SEQ ID NO: 14 ; And, the second polynucleotide, which comprises the nucleotide sequence shown in SEQ ID NO: 16, SEQ ID NO: 13 and SEQ ID NO: 15.
  • the present invention provides an isolated nucleic acid molecule encoding the monoclonal antibody or antigen-binding fragment thereof of the present invention as defined above.
  • the invention provides a vector comprising an isolated nucleic acid molecule as defined above.
  • the vector of the present invention can be a cloning vector or an expression vector.
  • the vectors of the present invention are, for example, plasmids, cosmids, bacteriophages and the like.
  • a host cell comprising the isolated nucleic acid molecule or vector of the present invention.
  • host cells include, but are not limited to, prokaryotic cells such as E. coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells and animal cells (such as mammalian cells, such as mouse cells, human cells, etc.).
  • the cells of the present invention can also be cell lines, such as 293T cells.
  • a method for preparing the monoclonal antibody of the present invention or an antigen-binding fragment thereof which comprises culturing the host cell of the present invention under suitable conditions, and recovering the monoclonal antibody of the present invention from the cell culture. Antibodies or antigen-binding fragments thereof.
  • the present invention provides a composition comprising the monoclonal antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector or host cell as described above.
  • the present invention provides a kit comprising the monoclonal antibody or antigen-binding fragment thereof of the present invention.
  • the monoclonal antibody or antigen-binding fragment thereof of the present invention further includes a detectable label.
  • the kit further includes a second antibody, which specifically recognizes the monoclonal antibody or antigen-binding fragment thereof of the present invention.
  • the second antibody further includes a detectable label.
  • detectable labels are well known to those skilled in the art, and include, but are not limited to, radioisotopes, fluorescent substances, luminescent substances, colored substances, enzymes (such as horseradish peroxidase) and the like.
  • the present invention provides a method for detecting the presence or level of a novel coronavirus or its S protein or S protein RBD in a sample, which includes using the monoclonal antibody or antigen-binding fragment thereof of the present invention.
  • the monoclonal antibody or antigen-binding fragment thereof of the present invention further includes a detectable label.
  • the method further includes using a second antibody carrying a detectable label to detect the monoclonal antibody or antigen-binding fragment thereof of the present invention.
  • the method can be used for diagnostic purposes (for example, the sample is a sample from a patient), or for non-diagnostic purposes (for example, the sample is a cell sample, not a sample from a patient).
  • the present invention provides a method for diagnosing whether a subject is infected with a novel coronavirus, which comprises: using the monoclonal antibody or antigen-binding fragment thereof of the present invention to detect the RBD of the novel coronavirus or its S protein or S protein Presence in a sample from the subject.
  • the monoclonal antibody or antigen-binding fragment thereof of the present invention further includes a detectable label.
  • the method further includes using a second antibody carrying a detectable label to detect the monoclonal antibody or antigen-binding fragment or anti-idiotypic antibody of the present invention.
  • the sample includes, but is not limited to, excrement, oral or nasal secretions, alveolar lavage fluid, etc. from a subject (such as a mammal, preferably a human).
  • the monoclonal antibody is an antibody comprising: the amino acid sequence of the VH CDR1-3 shown in SEQ ID NO: 1-3, and/or the amino acid sequence of the VH CDR1-3 shown in SEQ ID, respectively VL CDR1-3 shown in NO: 4-6; preferably, it includes: VH shown in SEQ ID NO: 7 and/or VL shown in SEQ ID NO: 8.
  • the detection method may use enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay, chemiluminescence immunoassay, radioimmunoassay, fluorescence immunoassay, immunochromatography, competition method and similar detection methods .
  • ELISA enzyme-linked immunosorbent assay
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof of the present invention, and a pharmaceutically acceptable carrier and/or excipient.
  • the monoclonal antibody includes: the amino acid sequence of the VH CDR1-3 shown in SEQ ID NO: 1-3, and/or the amino acid sequence of the VH CDR1-3 shown in SEQ ID NO: 4-6, respectively
  • the monoclonal antibody includes: VH as shown in SEQ ID NO: 7 and/or VL as shown in SEQ ID NO: 8.
  • the present invention provides a method for neutralizing the virulence of a novel coronavirus in a sample, which comprises contacting a sample containing the novel coronavirus with the monoclonal antibody or antigen-binding fragment thereof of the present invention.
  • a sample is a cell sample, not a patient or a sample from a patient.
  • the present invention provides the monoclonal antibody or antigen-binding fragment thereof as described above, which is used to neutralize the virulence of the novel coronavirus in a sample.
  • the present invention provides the monoclonal antibody or antigen-binding fragment thereof as described above, which is used to prevent or treat a novel coronavirus infection in a subject or a disease related to a novel coronavirus infection (such as a novel coronavirus infection). Viral pneumonia).
  • the present invention provides a method for preventing or treating a novel coronavirus infection or a novel coronavirus infection-related disease (such as novel coronavirus pneumonia) in a subject, which includes, giving a subject in need The person administers a prophylactic or therapeutically effective amount of the monoclonal antibody or antigen-binding fragment thereof of the present invention, or the pharmaceutical composition of the present invention.
  • the subject is a mammal, such as a human.
  • the monoclonal antibody or antigen-binding fragment thereof of the present invention or the pharmaceutical composition of the present invention can be administered to a subject by any appropriate route of administration.
  • administration routes include, but are not limited to, oral, buccal, sublingual, topical, parenteral, rectal, intrathecal, or nasal routes.
  • the monoclonal antibody is an antibody comprising: the amino acid sequence of the VH CDR1-3 shown in SEQ ID NO: 1-3, and/or the amino acid sequence of the VH CDR1-3 shown in SEQ ID, respectively VL CDR1-3 shown in NO: 4-6; preferably, it includes: VH shown in SEQ ID NO: 7 and/or VL shown in SEQ ID NO: 8.
  • the drugs and pharmaceutical compositions provided by the present invention can be used alone or in combination, and can also be used in combination with other pharmacologically active agents (for example, antiviral drugs, such as fapilavir, remdesivir, interferon, etc.).
  • the pharmaceutical composition further contains a pharmaceutically acceptable carrier and/or excipient.
  • the monoclonal antibody (such as the B38 antibody) of the present application can bind to the new coronavirus S protein RBD with high affinity, and has strong neutralizing activity against the new coronavirus.
  • the affinity of the B38 antibody of the present invention to RBD is 70.1 nM
  • the neutralization titer (half inhibitory concentration, IC 50 ) of the novel coronavirus is 0.177 ⁇ g/mL. Therefore, the monoclonal antibody (for example, the B38 antibody) of the present application has clinical application value for preventing and treating novel coronavirus infection.
  • Figure 1 shows the results of molecular sieve chromatography and SDS-PAGE detection of the new coronavirus S protein RBD.
  • Figure 2 shows the molecular sieve chromatography results and SDS-PAGE detection results of the recombinantly expressed B38 antibody.
  • the "-" on the gel chart indicates that DTT (non-reducing SDS-PAGE) is not added; “+” indicates that DTT (reduced SDS-PAGE).
  • Figure 3 shows the results of the kinetic curve of B38 antibody binding to RBD protein.
  • Figure 4 shows the cell surface fluorescence detected by BD FACSCanto in Example 6.
  • Figure 5 shows the neutralizing activity of different concentrations of B38 antibody against 2019-nCoV live virus.
  • the molecular biology experimental methods and immunoassay methods used in the present invention basically refer to J. Sambrook et al., Molecular Cloning: Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and FMAusubel et al., Compiled Molecular Biology Experiment Guide, 3rd Edition, John Wiley & Sons, Inc., 1995; the restriction enzymes are used in accordance with the conditions recommended by the product manufacturer. If no specific conditions are indicated in the examples, it shall be carried out in accordance with the conventional conditions or the conditions recommended by the manufacturer.
  • the reagents or instruments used without the manufacturer's indication are all conventional products that can be purchased commercially.
  • the inventors of the present application first used the S protein RBD of 2019-nCoV expressed in E. coli as the antigen, and through flow sorting, from the periphery of people who were infected with 2019-nCoV and recovered and discharged. From blood mononuclear cells (PBMCs), memory B cells that can specifically bind to the S protein RBD are screened, and then RT-PCR is performed on the single B cells obtained from the screening to obtain the sequence encoding the variable region of the antibody. Furthermore, the sequence encoding the variable region of the antibody and the constant region gene are linked to an expression vector, and expressed and purified in mammalian cells to obtain antibody B38.
  • PBMCs blood mononuclear cells
  • antibody B38 can specifically bind to S protein RBD, block the binding of S protein RBD to ACE2, inhibit the infection of human cells by 2019-nCoV, and has anti-2019-nCoV infection. Neutralizing activity.
  • the DNA fragment encoding the 2019-nCoV/2019 strain spike protein S protein RBD (the amino acid sequence of which is shown in SEQ ID NO: 17) was ligated to the pET21a vector, and the DNA fragment was in the coding region A nucleotide sequence encoding a 6*histidine tag (6*His tag) and a stop codon are also attached to the 3'end of the.
  • Example 2 Isolation of memory B cells that specifically recognize RBD protein
  • PBMCs were washed twice with PBS. Subsequently, PBMCs were sorted with FACSAria III, PE - Cy5 - APC - APC - Cy7 + Pacific Blue + FITC + PE + cells (ie, B cells) were collected, and directly collected into a 96-well plate, 1 cell/well.
  • Example 3 Isolation and identification of B38 antibody and construction of recombinant expression vector
  • Superscript III reverse transcriptase (Invitrogen) was used to perform reverse transcription on the B cells obtained in Example 2 (at 55° C. for 60 minutes), wherein the reverse transcription primers used are shown in Table 2.
  • PCRa PCRa
  • HotStar Tap Plus enzyme QIAgen
  • the reaction conditions used As follows: 95°C, 5min; 35 cycles (95°C 30s, 55°C (heavy chain/ ⁇ chain) 30s, 72°C 90s); 72°C, 7min.
  • PCRb the second round of PCR
  • the primers used are shown in Table 4; the reaction conditions used are as follows: 95°C, 5min; 35 cycles of (95°C) 30s, 58°C (heavy chain)/60°C ( ⁇ chain)/64°C ( ⁇ chain) 30s, 72°C (90s); 72°C, 7min.
  • the PCR products were separated by 1% agarose gel electrophoresis.
  • the PCR product with a band size of 400-500bp was recovered and sent to a sequencing company for sequencing.
  • the sequencing results were analyzed with NCBI online software.
  • B38 The amino acid sequence of the heavy chain variable region of the B38 antibody is shown in SEQ ID NO: 7 (the coding gene is shown in SEQ ID NO: 12), and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 8 (coding The gene is shown in SEQ ID NO: 13).
  • SEQ ID NO: 7 the coding gene is shown in SEQ ID NO: 12
  • SEQ ID NO: 8 the amino acid sequence of the light chain variable region
  • SEQ ID NO: 13 The sequence identity between the B38 antibody and germline genes is shown in Table 5-6 below.
  • the nucleotide sequence encoding the heavy chain/light chain variable region obtained by the analysis was connected to the corresponding nucleotide sequence encoding the heavy chain/ ⁇ chain constant region by bridging PCR, and then cloned into the expression vector pCAGGS( Purchased from Addgene) to obtain recombinant expression vectors encoding antibody heavy and light chains, respectively.
  • the construction scheme of the construct expressing the heavy chain and the light chain is as follows:
  • Heavy chain coding sequence (5’-3’): CMV promoter-EcoR I restriction site-Leader sequence gene-VH gene-CH gene-Xho I restriction site;
  • Light chain ( ⁇ ) coding sequence (5’-3’): CMV promoter-Sac I restriction site-Leader sequence gene-VL gene-CL ( ⁇ ) gene-Xho I restriction site;
  • the amino acid sequence of the leader sequence is shown in SED ID NO: 11 (the coding gene is shown in SEQ ID NO: 16), and the amino acid sequence of CH is shown in SED ID NO: 9 (the coding gene is shown in SEQ ID NO: 14). (Shown), the amino acid sequence of CL is shown in SED ID NO: 10 (the coding gene is shown in SEQ ID NO: 15).
  • Biacore 8K (Biacore Inc.) is used to perform surface plasmon resonance analysis. Specific steps are as follows:
  • the anti-human IgG antibody is immobilized on the flow cell (Fc) of the CM5 chip by means of amino coupling.
  • the fixed amount is controlled at around 8,000 response units (RU).
  • RU response units
  • the RBD protein was diluted with a solution of 20 mM HEPES, 150 mM NaCl, pH 7.4 in successive times.
  • the serially diluted RBD protein was sequentially passed through each channel (starting with a low concentration and loaded one by one).
  • the gene encoding hACE2 protein (Genbank accession number: NP_068576.1) was cloned into the pEGFP-N1 vector (purchased from Addgene), and the gene can be fused and expressed with the gene encoding GFP to construct a plasmid pEGFP-hACE2.
  • the plasmid pEGFP-hACE2 was transfected into HEK293T cells. After 24h, the expression of GFP can be observed under a fluorescence microscope. Collect HEK293T-hACE2 cells. The irrelevant antibody was incubated with 200ng/mL RBD protein at a molar ratio of 10:1 for 1h at room temperature.
  • HEK293T-hACE2 cells (2x10 5 /reaction) were incubated with the RBD protein (200ng/ml, carrying 6*His tag) incubated with irrelevant antibodies for 30min at room temperature. After centrifugation at 500xg for 5 min, the supernatant was removed, and the cells were washed twice with PBS. Subsequently, the cells were incubated with anti-His/APC (Miltenyi Biotec, 130-119-820) at room temperature for 30 minutes, and then washed twice with PBS, and then the fluorescence on the cell surface was detected with BD FACSCanto.
  • RBD protein 200ng/ml, carrying 6*His tag
  • the B38 antibody purified in Example 4 was incubated with 200 ng/mL RBD protein at a molar ratio of 10:1 for 1 h at room temperature, and then incubated with HEK293T-hACE2 cells. Then, as described above, use anti-His/APC to detect the binding of RBD protein to cells. The result is shown in Figure 4.
  • Figure 4 shows the cell surface fluorescence detected by BD FACSCanto.
  • the B38 antibody purified in Example 4 was diluted from 200 ⁇ g/mL to the 12th gradient (0.098 ⁇ g/mL), and then respectively compared with the BetaCoV/Shenzhen/SZTH-003/2020 of half the tissue culture infectious dose (TCID 50)
  • the virus obtained from Shenzhen Third People's Hospital, GISAID number: EPI_ISL_406594
  • CPE cytopathic effect
  • Figure 5 shows the neutralizing activity of different concentrations of B38 antibody against 2019-nCoV live virus.
  • the results showed that the neutralizing titer (half inhibitory concentration, IC 50 ) of the B38 antibody against the live 2019-nCoV virus was 0.177 ⁇ g/mL, which has excellent neutralizing activity.

Abstract

L'invention concerne un anticorps monoclonal contre le nouveau coronavirus, et une composition (telle qu'un agent de diagnostic et un agent thérapeutique) contenant l'anticorps. De plus, l'invention concerne également l'utilisation de l'anticorps. L'anticorps peut être appliqué au diagnostic, à la prévention et/ou au traitement d'une infection par le nouveau coronavirus et/ou de maladies provoquées par l'infection (telle qu'une pneumonie à nouveau coronavirus).
PCT/CN2020/079718 2020-03-06 2020-03-17 Anticorps monoclonal contre le nouveau coronavirus et son utilisation WO2021174594A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010151350.3A CN113354730B (zh) 2020-03-06 2020-03-06 一种抗新型冠状病毒的单克隆抗体及其应用
CN202010151350.3 2020-03-06

Publications (1)

Publication Number Publication Date
WO2021174594A1 true WO2021174594A1 (fr) 2021-09-10

Family

ID=77523966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/079718 WO2021174594A1 (fr) 2020-03-06 2020-03-17 Anticorps monoclonal contre le nouveau coronavirus et son utilisation

Country Status (2)

Country Link
CN (1) CN113354730B (fr)
WO (1) WO2021174594A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102692A1 (fr) * 2021-12-06 2023-06-15 广州医科大学附属市八医院 Anticorps humains et combinaisons d'anticorps pour neutralisation synergique de sars-cov-2 et leur utilisation
WO2023108936A1 (fr) * 2021-12-14 2023-06-22 杭州安旭生物科技股份有限公司 Anticorps neutralisant capable de se lier au virus sars-cov-2 et son utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114560929B (zh) * 2022-03-21 2023-07-04 深圳国家感染性疾病临床医学研究中心 针对冠状病毒np蛋白的单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1450164A (zh) * 2003-06-11 2003-10-22 复旦大学 一种新型冠状病毒株及其医药用途
CN109666070A (zh) * 2017-10-13 2019-04-23 清华大学 单克隆抗体mers-4v2及其编码基因和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522208A (zh) * 2005-02-08 2009-09-02 纽约血库公司 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体
CN104628849B (zh) * 2013-11-14 2018-04-10 清华大学 单克隆抗体mers‑4及其编码基因和应用
CN105934441A (zh) * 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
CN103864924B (zh) * 2014-02-14 2016-09-07 中国科学院微生物研究所 一种中东呼吸综合征冠状病毒抗体及其制备方法
CN104447986B (zh) * 2014-12-23 2017-12-29 中国科学院微生物研究所 一种中东呼吸综合征冠状病毒中和抗体及其制备方法
US10676511B2 (en) * 2015-09-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
CN106380517B (zh) * 2016-10-28 2019-07-16 中国人民解放军军事医学科学院微生物流行病研究所 一种对中东呼吸综合征冠状病毒具有中和活性的小分子抗体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1450164A (zh) * 2003-06-11 2003-10-22 复旦大学 一种新型冠状病毒株及其医药用途
CN109666070A (zh) * 2017-10-13 2019-04-23 清华大学 单克隆抗体mers-4v2及其编码基因和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIANHONG ZOU, YU, JIANG; WEN, XIAO; FANG, CHEN; XIE-HONG, LIU: "The Research Progress of Novel coronavirus (2019-nCoV)", JOURNAL OF PRACTICAL SHOCK, 1 January 2020 (2020-01-01), pages 32 - 35, XP055842423, ISSN: 2096-4544 *
QIAN ZHANG, FENG, ZHENQING: "Antibody strategies against the novel coronavirus pneumonia", ACTA UNIVERSITATIS MEDICINALIS NANJING (NATURAL SCIENCE), vol. 40, no. 2, 15 February 2020 (2020-02-15), pages 155 - 159, XP055842409, ISSN: 1007-4368, DOI: 10.7655/NYDXBNS20200202 *
TIAN, X.L. ET AL.: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody", EMERGING MICROBES & INFECTIONS, vol. 9, no. 1, 17 February 2020 (2020-02-17), XP055736759, DOI: 10.1080/22221751.2020.1729069 *
XIA LIQIU: "Research Progress on New Coronavirus SARS-CoV-2", JIGUANG SHENGWU XUEBAO - ACTA LASER BIOLOGY SINICA, 1 January 2020 (2020-01-01), pages 1 - 10, XP055842438, ISSN: 1007-7146 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102692A1 (fr) * 2021-12-06 2023-06-15 广州医科大学附属市八医院 Anticorps humains et combinaisons d'anticorps pour neutralisation synergique de sars-cov-2 et leur utilisation
WO2023108936A1 (fr) * 2021-12-14 2023-06-22 杭州安旭生物科技股份有限公司 Anticorps neutralisant capable de se lier au virus sars-cov-2 et son utilisation

Also Published As

Publication number Publication date
CN113354730B (zh) 2022-06-07
CN113354730A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
WO2021174595A1 (fr) Anticorps monoclonal pour le nouveau coronavirus résistant et son utilisation
WO2021180218A1 (fr) Anticorps monoclonal dirigé contre un nouveau coronavirus et son application
JP6783886B2 (ja) 抗ｃｔｌａ４モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
KR101671452B1 (ko) 항ｒｓｖ ｇ 단백질 항체
WO2021174594A1 (fr) Anticorps monoclonal contre le nouveau coronavirus et son utilisation
CN113943368B (zh) 一种新型冠状病毒及其突变体的单克隆抗体及其应用
JP2008518602A (ja) 抗呼吸器多核体ウイルス抗体、抗原、およびそれらの用途
CN116063464A (zh) 冠状病毒的抗体或其抗原结合片段
TWI705974B (zh) Rsv-專一性抗體及其功能性部位
CN113929774A (zh) 一种新型冠状病毒及其突变体的单克隆抗体及其应用
US9017668B2 (en) High affinity human antibodies to human cytomegalovirus (CMV) gB protein
WO2020029860A1 (fr) Anticorps bispécifique contre le virus de la rage et son application
CN113444169A (zh) 新型冠状病毒的人源单克隆抗体及其应用
WO2022105772A1 (fr) Anticorps bispécifique ayant une activité neutralisante contre le coronavirus et son utilisation
CN112574300B (zh) 抗sar-cov-2全人源单克隆抗体及其制法与应用
WO2022127793A1 (fr) Molécule de liaison spécifique du virus respiratoire syncytial
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
CN115043938A (zh) SARS-CoV-2及其突变株的抗体及应用
CN115515976A (zh) 冠状病毒抗体
CN116836269A (zh) 抗呼吸道合胞病毒的单克隆抗体及其应用
WO2021218947A1 (fr) Anticorps monoclonal contre le nouveau coronavirus et son utilisation
US20230399385A1 (en) Neutralizing antibodies against sars-cov-2
CN110437332B (zh) 一种抗病毒感染的sftsv蛋白结合分子
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法
CN114075283A (zh) 结合人cd38的抗体、其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20923220

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20923220

Country of ref document: EP

Kind code of ref document: A1